Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)
|Synonyms||MEDI9929, AMG 157|
|Chemical and physical data|
|Molar mass||144.6 kDa g·mol−1|
Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
Structural studies by X-ray crystallography showed that Tezepelumab competes against a critical part of the TSLPR binding site on TSLP
- Verstraete, Kenneth; Peelman, Frank; Braun, Harald; Lopez, Juan; Van Rompaey, Dries; Dansercoer, Ann; Vandenberghe, Isabel; Pauwels, Kris; Tavernier, Jan (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1). doi:10.1038/ncomms14937. ISSN 2041-1723. PMC 5382266. PMID 28368013.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Tezepelumab, American Medical Association.
- World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- Tezepelumab granted Breakthrough Therapy Designation by US FDA - AstraZeneca Press Release
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|